{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:47:31Z","timestamp":1785840451134,"version":"3.56.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.vaccine.2021.08.013","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T08:50:54Z","timestamp":1629363054000},"page":"5615-5625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Cellular and humoral immunity following vaccination with two different PCV2 vaccines (containing PCV2a or PCV2a\/PCV2b) and challenge with virulent PCV2d"],"prefix":"10.1016","volume":"39","author":[{"given":"Cristina","family":"Venegas-Vargas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas P.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis L.","family":"Foss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci K.","family":"Godbee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2349-0818","authenticated-orcid":false,"given":"Meggan","family":"Bandrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.08.013_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2013.00114","article-title":"Mechanisms of action of adjuvants","volume":"4","author":"Awate","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.08.013_b0010","doi-asserted-by":"crossref","unstructured":"Bandrick, M., Guti\u00e9rrez, A.H., Desai, P., Rincon, G., Martin, W.D., Terry, F.E., Groot, A.S.d., Foss, D.L., 2020. T cell epitope content comparison (EpiCC) analysis demonstrates a bivalent PCV2 vaccine has greater T cell epitope overlap with field strains than monovalent PCV2 vaccines. Veterinary Immunol Immunopathol 223.","DOI":"10.1016\/j.vetimm.2020.110034"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.013_b0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.tvjl.2012.06.031","article-title":"Commercial porcine circovirus type 2 vaccines: efficacy and clinical application","volume":"194","author":"Chae","year":"2012","journal-title":"Veterinary J"},{"key":"10.1016\/j.vaccine.2021.08.013_b0020","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/eji.201444543","article-title":"Squalene emulsion potentiated the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases IL-18, and IFN-g","volume":"45","author":"Desbien","year":"2015","journal-title":"Eur J Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2021.08.013_b0025","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1128\/JVI.78.12.6297-6303.2004","article-title":"A chimeric porcine circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2 (PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces protective immunity against PCV2 infection in pigs","volume":"78","author":"Fenaux","year":"2004","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.013_b0030","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1297-9716-45-44","article-title":"Memory T cell proliferative responses and IFN-\u03b3 productivity sustain long-lasting efficacy of a Cap-based PCV2 vaccine upon PCV2 natural infection and associated disease","volume":"45","author":"Ferrari","year":"2014","journal-title":"Vet Res"},{"issue":"24","key":"10.1016\/j.vaccine.2021.08.013_b0035","doi-asserted-by":"crossref","first-page":"12813","DOI":"10.1128\/JVI.01719-09","article-title":"Insights into the evolutionary history of an emerging livestock pathogen: porcine circovirus 2","volume":"83","author":"Firth","year":"2009","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2021.08.013_b0040","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.vaccine.2007.12.019","article-title":"Porcine circovirus type 2 (PCV2) vaccination of conventional pigs prevents viremia against PCV2 isolates of different genotypes and geographic origins","volume":"26","author":"Fort","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.013_b0045","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.vetimm.2008.12.024","article-title":"Development of cell-mediated immunity to porcine circovirus type 2 (PCV2) in caesarean-derived, colostrum-deprived piglets","volume":"129","author":"Fort","year":"2009","journal-title":"Vet Immunol Immunopathol."},{"issue":"30","key":"10.1016\/j.vaccine.2021.08.013_b0050","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1016\/j.vaccine.2009.04.028","article-title":"One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and significantly reduces PCV2 viremia in an experimental model","volume":"27","author":"Fort","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.013_b0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2055-5660-1-3","article-title":"Serum haptoglobin dynamics in pigs vaccinated or not vaccinated against porcine circovirus type 2","volume":"1","author":"Fraile","year":"2015","journal-title":"Porcine Health Manage"},{"issue":"12","key":"10.1016\/j.vaccine.2021.08.013_b0060","doi-asserted-by":"crossref","first-page":"e0208585","DOI":"10.1371\/journal.pone.0208585","article-title":"Porcine circovirus 2 (PCV-2) genotype update and proposal of a new genotyping methodology","volume":"13","author":"Franzo","year":"2018","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.013_b0065","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1297-9716-42-50","article-title":"Optimal combinations of acute phase proteins for detecting infectious disease in pigs","volume":"42","author":"Heegaard","year":"2011","journal-title":"Vet Res"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.013_b0070","doi-asserted-by":"crossref","DOI":"10.1186\/s12917-020-02549-3","article-title":"Genetic diversity and different cross-neutralization capability of porcine circovirus type 2 isolates recently circulating in South Korea","volume":"16","author":"Kang","year":"2020","journal-title":"BMC Veterinary Res"},{"issue":"17","key":"10.1016\/j.vaccine.2021.08.013_b0075","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.vaccine.2011.02.034","article-title":"Comparative efficacy of commercial Mycoplasma hyopneumoniae and porcine circovirus 2 (PCV2) vaccines in pigs experimentally infected with M. hyopneumoniae and PCV2","volume":"29","author":"Kim","year":"2011","journal-title":"Vaccine"},{"issue":"3-4","key":"10.1016\/j.vaccine.2021.08.013_b0080","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.vetmic.2013.03.013","article-title":"Amino acid mutations in the capsid protein produce novel porcine circovirus type 2 neutralizing epitopes","volume":"165","author":"Liu","year":"2013","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2021.08.013_b0085","doi-asserted-by":"crossref","unstructured":"Meerts, P., Misinzo, G., Lefebvre, D., Nielsen, J., B\u00f8tner, A., Kristensen, C.S., Nauwynck, H.J., 2006. Correlation between the presence of neutralizing antibodies against porcine circovirus 2 (PCV2) and protection against replication of the virus and development of PCV2-associated disease. BMC Veterinary Res 2, (30 January 2006).","DOI":"10.1186\/1746-6148-2-6"},{"key":"10.1016\/j.vaccine.2021.08.013_b0090","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1099\/vir.0.041749-0","article-title":"Protective effect of the maternally derived porcine circovirus type 2 (PCV2)-specific cellular immune response in piglets by dam vaccination against PCV2 challenge","volume":"93","author":"Oh","year":"2012","journal-title":"J General Virol"},{"issue":"2012","key":"10.1016\/j.vaccine.2021.08.013_b0095","first-page":"4341","article-title":"The mechanism of action of MF59 - An innately attractive adjuvant formaultion","volume":"30","author":"O'Hagen","year":"2012","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2021.08.013_b0100","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.vaccine.2020.01.013","article-title":"Porcine circovirus type 2a or 2b based experimental vaccines provide protection against PCV2d\/porcine parvovirus 2 co-challenge","volume":"38","author":"Opriessnig","year":"2020","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2021.08.013_b0105","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.vaccine.2008.11.105","article-title":"Comparison of efficacy of commercial one dose and two dose PCV2 vaccines using a mixed PRRSV\u2013PCV2\u2013SIV clinical infection model 2\u20133-months post vaccination","volume":"27","author":"Opriessnig","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.013_b0110","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1128\/CVI.00497-12","article-title":"Comparative effects of vaccination against porcine circovirus type 2 (PCV2) and porcine reproductive and respiratory syndrome virus (PRRSV) in a PCV2-PRRSV challenge model","volume":"20","author":"Park","year":"2013","journal-title":"Clin Vaccine Immunol CVI"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.013_b0115","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1128\/CVI.00768-13","volume":"21","author":"Park","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.013_b0120","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.tvjl.2014.05.025","article-title":"Comparison of the immunoperoxidase monolayer assay and three commercial ELISAs for detection of antibodies against porcine circovirus type 2","volume":"201","author":"Pileri","year":"2014","journal-title":"Veterinary J"},{"issue":"4","key":"10.1016\/j.vaccine.2021.08.013_b0125","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.cell.2006.02.019","article-title":"Translating Innate Immunity into Immunological Memory: Implications for Vaccine Development","volume":"124","author":"Pulendran","year":"2006","journal-title":"Cell"},{"issue":"1-2","key":"10.1016\/j.vaccine.2021.08.013_b0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.vetmic.2011.11.030","article-title":"Antigenic subtyping and epitopes\u2019 competition analysis of porcine circovirus type 2 using monoclonal antibodies","volume":"157","author":"Saha","year":"2012","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2021.08.013_b0135","doi-asserted-by":"crossref","unstructured":"Saha, D., Lefebvre, D.J., Ooms, K., Huang, L., Delputte, P.L., Doorsselaere, J.v., Nauwynck, H.J., 2012b. Single amino acid mutations in the capsid switch the neutralization phenotype of porcine circovirus 2. J General Virol 93, 1548\u20131555.","DOI":"10.1099\/vir.0.042085-0"},{"issue":"6","key":"10.1016\/j.vaccine.2021.08.013_b0140","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/tbed.13596","article-title":"Detection and genotyping of Porcine circovirus 2 (PCV-2) and detection of Porcine circovirus 3 (PCV-3) in sera from fattening pigs of different European countries","volume":"67","author":"Saporiti","year":"2020","journal-title":"Transboundary Emerg Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2021.08.013_b0145","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/pathogens9070533","article-title":"Frequency of Detection and Phylogenetic Analysis of Porcine circovirus 3 (PCV-3) in Healthy Primiparous and Multiparous Sows and Their Mummified Fetuses and Stillborn","volume":"9","author":"Saporiti","year":"2020","journal-title":"Pathogens"},{"issue":"1-2","key":"10.1016\/j.vaccine.2021.08.013_b0150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.virusres.2011.10.007","article-title":"Porcine circovirus type 2 (PCV2) infections: Clinical signs, pathology and laboratory diagnosis","volume":"164","author":"Segal\u00e9s","year":"2012","journal-title":"Virus Res"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.013_b0155","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1586\/14760584.2015.983084","article-title":"Best practice and future challenges for vaccination against porcine circovirus type 2","volume":"14","author":"Segal\u00e9s","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.013_b0160","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.rvsc.2014.04.007","article-title":"Comparative analyses of humoral and cell-mediated immune responses upon vaccination with different commercially available single-dose porcine circovirus type 2 vaccines","volume":"97","author":"Seo","year":"2014","journal-title":"Res Vet Sci"},{"key":"10.1016\/j.vaccine.2021.08.013_b0165","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1099\/vir.0.000100","article-title":"Global molecular genetic analysis of porcine circovirus type 2 (PCV2) sequences confirms the presence of four main PCV2 genotypes and reveals a rapid increase of PCV2d","volume":"96","author":"Xiao","year":"2015","journal-title":"J General Virol"},{"key":"10.1016\/j.vaccine.2021.08.013_b0170","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.vetmic.2016.11.009","article-title":"PCV2d-2 is the predominant type of PCV2 DNA in pig samples collected in the U.S. during 2014\u20132016","volume":"197","author":"Xiao","year":"2016","journal-title":"Vet Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.013_b0175","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1111\/tbed.12768","article-title":"Phylogenetic and genetic variation analyses of porcine circovirus type 2 isolated from China","volume":"65","author":"Yang","year":"2017","journal-title":"Transboundary Emerg Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2021.08.013_b0180","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1089\/vim.2015.0021","article-title":"Correlates of protection following vaccination with inactivated porcine circovirus 2 vaccines","volume":"28","author":"Zanotti","year":"2015","journal-title":"Viral Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21010331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21010331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:04:48Z","timestamp":1759403088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21010331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":36,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0264410X21010331"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.013","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular and humoral immunity following vaccination with two different PCV2 vaccines (containing PCV2a or PCV2a\/PCV2b) and challenge with virulent PCV2d","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}